All In Biotech

Drug Trial Radar · NCT06690242

MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease

A Multicenter, Randomized,Positive Controlled, and Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of MT1013 Injection in Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism Undergoing Maintenance Hemodialysis

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Nov 4, 2024

Primary completion

Aug 30, 2025

Study completion Aug 30, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.

Conditions

  • Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Interventions

  • MT1013Drug

    MT1013 is a novel calcimimetic agent

  • MT1013Drug

    MT1013 is a novel calcimimetic agent

  • Etelcalcetide HydrochlorideDrug

    the already-marketed therapeutic agents

  • PlaceboDrug

    The measure does not contain the active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with > 30% reduction from baseline in mean iPTH during the efficacy assessment phaseTime frame: Weeks 22 to 27, inclusive

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.